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LETTER
Metal-free domino amination-Knoevenagel condensation approach to access
new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR
Essam M. Eliwa a,b, Marcel Fresea, Ahmed H. Halawab, Maha M. Soltan c, Larissa V. Ponomareva d,e,
Jon S. Thorson d,e, Khaled A. Shaaban d,e, Mohamed Shaaban a,f, Ahmed M. El-Agrody b and
Norbert Sewald a
aOrganic and Bioorganic Chemistry, Faculty of Chemistry, Bielefeld University, Bielefeld, Germany; bChemistry Department, Faculty of Science,
Al-Azhar University, Nasr City-Cairo, Egypt; cBiology Unit, Central Laboratory for Pharmaceutical and Drug Industries Research Division,
Chemistry of Medicinal Plants Department, Pharmaceutical and Drug Industries Research Division, National Research Centre Cairo, Egypt;
dCenter for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, USA; eDepartment of Pharmaceutical Sciences,
College of Pharmacy, University of Kentucky, Lexington, , USA; fChemistry of Natural Compounds Department, Pharmaceutical and Drug
Industries Research Division, National Research Centre, Dokki-Cairo, Egypt
ABSTRACT
A metal-free, atom-economy and simple work-up domino amination-Knoevenagel condensation
approach to construct new coumarin analogous (4a-f and 8a-e) was described. Further, new
formyl (5a,d-f) and nitro (9a,d-f) coumarin derivatives were synthesized via C-N coupling
reaction of various cyclic secondary amines and 4-chloro-3-(formyl-/nitro)coumarins (1a,c),
respectively. The confirmed compounds were screened for their in vitro anti-proliferative activity
against KB-3-1, A549 and PC3 human cancer cell lines using resazurin cellular-based assay.
Among them, coumarin derivatives 4e and 8e displayed the best anti-cervical cancer potency
(KB-3-1) with IC50 values of 15.5 ± 3.54 and 21 ± 4.24 µM, respectively. Also, 4e showed the
most promising cytotoxicity toward A549 with IC50 value of 12.94 ± 1.51 µM. As well, 9d
presented a more significant impact of potency against PC3 with IC50 7.31 ± 0.48 µM. Moreover,
8d manifested selectivity against PC3 (IC50 = 20.16 ± 0.07 µM), while 8e was selective toward
KB-3-1 cell line (IC50 = 21 ± 4.24 µM). Matching with docking profile, the enzymatic assay
divulged that 8e is a dual potent single-digit nanomolar inhibitor of VEGFR-2 and EGFR with
IC50 values of 24.67 nM and 31.6 nM that were almost equipotent to sorafenib (31.08 nM) and
erlotinib (26.79 nM), respectively.
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Cancer remains one of the most daunting diseases to
treat, thus, the development of new antitumor agents
is still a very critical research domain. Amongst the
attractive therapeutic targets for cancer, protein tyrosine
kinases (PTKs) that regulate the biological potency of
proteins by phosphorylation process that play a crucial
role in signal transduction mechanisms by which inter-
cellular signals regulate significance intra-cellular func-
tions such as ion transport, cellular proliferation, differ-
entiation, angiogenesis, and hormone responses.
Among them, the epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor receptor
(VEGFR) are receptor protein tyrosine kinases (RPTKs)
that overexpressed or mutated in several tumors due
to a mutation of a normal gene to an oncogene [1].
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EGFR (a dimer of HER-1 and HER-2) and VEGFR-2 (KDR, a
type of VEGFRs) are pro-angiogenic growth factor recep-
tors that induce angiogenesis process in order to estab-
lish new blood vessels that have an important role in
tumor growth and metastasis; therefore, they are attrac-
tive therapy targets and dominant strategy for the treat-
ment of cancer [1-6].
VEGFR-2 type II inhibitors shared essential pharmaco-
phoric features encompassing: (i) terminal heteroaro-
matic ring that occupies the ATP binding pocket
(hinge region) via H-bond with cysteine acid (like
Cys917); (ii) oxygen (N or S) linker that occupies the gate-
keeper region between the hinge and DFG domains; (iii)
urea or amide moiety spacer as H-bond acceptor–donor
pair (HBA–HBD) that binds to DFG motif via H-bonds
with glutamic (Glu833) and aspartic (Asp1044) acids;
(iv) terminal lipophilic group that occupies the allosteric
hydrophobic pocket (DFG-out) via hydrophobic inter-
actions [7-11]. The well-defined EGFR inhibitors consists
of: (i) central hetero aromatic unit that fits the adenine
binding site through H-bond with methionine amino
acid residue (Met793); (ii) hydrophobic head is a
phenyl binding group with various hydrophobic substi-
tuents to interact with the hydrophobic region I; (iii)
nitrogen spacer to link the hinge-binding central
moiety with the terminal fragment that occupies the
hydrophobic region I; (iv) hydrophobic tail is directly
linked to the central heteroaromatic core and induced
fit to the hydrophobic region II [12].
Coumarins are versatile oxygen-containing hetero-
cyclic molecules in the medicinal chemistry domain
due to their aspirational biological applications [13,14].
Particularly, they have anti-coagulant, anti-oxidant [15],
anti-microbial, anti-viral [16–18], anti-cancer [19–24],
anti-diabetic, analgesic, anti-neurodegenerative, and
anti-inflammatory properties [17,25]. Interestingly,
several coumarin derivatives obtained via Knoevenagel
condensation reactions have been proved to be potent
enzymes inhibitors [26–28]. Also, Knoevenagel reaction
products are significant key intermediates for the syn-
thesis of many marketed drugs such as atorvastatin
(Lipitor®) and pioglitazone (Actos®) [29].
The recently developed transition-metal-catalyzed
reactions have been confirmed as useful protocols for
the synthesis of heterocyclic compounds as well.
However, most of these approaches suffer from some
drawbacks encompassing complex procedures (e.g.
high expense, moisture sensitivity and toxicity nature
of many of these metal catalysts and ligands). Conse-
quently, studies of eco-friendly organic transformations
using commercially accessible and cost-efficient
reagents have also been recently extended [30–33].
Multi-component transformation domino reactions are
a formidable and significant method in the organic syn-
thesis domain due to their benefits to our environment
and natural resources [34].
Synthesis and investigation of heterocyclic/aryl
amines still cornerstone research area in medicinal
chemistry and its neighboring disciplines. In particular,
due to their high prospective to demonstrate potent
biological activity and their application as lead com-
pounds in drug design, as well as they are vital building
blocks of various organic compounds [30]. The most
effective methodology for the construction of hetero-
cyclic/aryl amines is the C–N cross-coupling reaction
between heterocyclic/aryl halides and primary or sec-
ondary amines via the Buchwald–Hartwig reaction
using high-expensive phosphine-ligated palladium pre-
catalysts [35]. As a result, a daunting application in the
pharmaceutical industry. Hence, the development of
metal-free C–N coupling reactions is a surrogate trend
and hold a prominent position [30,31].
Spur by the aforementioned facts and our persistent
research efforts to explore highly effective and con-
venient synthetic routes for the synthesis of bioactive
molecules [22,24], we present in this research paper an
efficient cascade amination-Knoevenagel strategy for
the construction of new coumarin derivatives under
metal-free conditions. Their anti-proliferative activity
was evaluated against KB-3-1, A549 and PC3 cell lines
using resazurin cellular assay. Moreover, we highlighted
the in silico computational predictions including phys-
icochemical features and biological targets of the
active compounds. Furthermore, molecular docking of
the most robust compounds 4e, 8e and 9d as potential
inhibitors of vascular endothelial growth factor receptor
(VEGFR-2) and epidermal growth factor receptor (EGFR)
biomolecular targets was performed. Experimentally,
an enzymatic assay for the promising dual inhibitors of
VEGFR-2 and EGFR was investigated as well, delivering
very potent inhibitory activities.
2. Results and discussion
2.1. Chemistry
In the preliminary investigation, we tried a model reac-
tion of 4-chloro-3-formylcoumarin (1a) as an example
of α,β-unsaturated-β-haloaldehydes [36,37], acidic CH2
called methyl cyanoacetate (2a), and a cyclic secondary
amine named pyrrolidine (3a) in ethanol (EtOH) at room
temperature. As a result, compound 4a was generated
with 65% yield in 40 min (Table 1, entry 1). As previously
reported [38,39], in nucleophilic aromatic substitution
(SNAr)-Knoevenagel condensation domino reaction, the
amine plays twofold role as a nucleophilic and base,
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hence, the produced HCl was neutralized with an excess
of amine or additional base to perform the reaction in
smoothly way. Consequently, the reactants ratio of 1a
(1 equiv), 2a (1 equiv), and 3a (2.5 equiv) was used as
an optimized reaction condition (Table 1). Also, the
yield was further investigated by utilizing different sol-
vents such as methanol (MeOH), dichloromethane
(DCM), and water. We observed that MeOH was
premium for the reaction and afforded 4a in the best
yield (Table 1, entry 3). All the optimization trials were
carried out under oxygen and air atmospheres (open
flask).
Once the optimal reaction conditions had been estab-
lished (Table 1, entry 3), we explored the scope and gen-
erality of the tandem approach (Scheme 1). A variety of
cyclic secondary amines [piperidine (3b), 4-hydroxypi-
peridine (3c), and morpholine (3d)] were used and to
our delight, all the corresponding desired products 4b-
d were obtained in excellent yields (91–96%) and
purified by simple recrystallization/washing with hot
MeOH where we did not need to perform the column
chromatography work-up as in the previously reported
methods [38,39].
In the case of the bifunctional amine that called; 4-
(aminomethyl)piperidine (4-AMP, 3e), we got 4e as an
exclusive and regiospecific product [40–4z3] in high
yield instead of 4e′ (Scheme 2). Our interpretation
based on the concept; nucleophilicity is much more sen-
sitive to steric effects than basicity, thus in this case
primary amine (−CH2NH2) is more nucleophilic than
the secondary one (−CH2NHCH2−) and consider as the
preference orientation. The obtained secondary amine
4e can be easily identified from the 1H NMR spectrum
by the characteristic 1H chemical shift of aromatic
triplet NH at δ 8.76 ppm (see Figure S13, Supporting
Information). Also, it seems worthwhile to point out
that 4e among this series showed [M + H]+ adduct ion
in (+)-ESI-MS, while all the others exhibited [M + Na]+
molecular ion peaks.
Under the aforementioned conditions, our reconnais-
sance was expanded to utilize imidazole (3f) instead of
the above-mentioned amines in an attempt to get the
desirable product 4f′ , astonishingly, 4-methoxy cou-
marin derivative 4f was isolated in 89% yield
(Scheme 2). Unambiguously, imidazole dealing with
the reaction as a nucleophilic organocatalyst (covalent
catalyst) by forming a covalent bond with 1a [44] to
produce a reactive intermediate because the positively
charged nitrogen makes imidazole a very good leaving
group and subsequently promoted the MeOH to attack
the intermediate. Hence, imidazole hydrochloride may
be catalyzed Knoevenagel condensation reaction in
the next step to furnish 4f (Scheme 3). NMR data of 4f
manifested the new methoxy 1H resonance at δ 4.13
and the corresponding 13C chemical shift at δ
63.8 ppm. The (+)-ESI-MS analysis of compound 4f
proved its molecular weight as 285 Da, where it
showed the molecular ion peak at m/z 308 [M + Na]+
(see Supporting Information, Figs. S16–S18).
Having in mind the previous studies [38,45], we
propose that the cascade one-pot reaction mechanism
could be implemented via two routes as depicted in
Table 1. Optimization of domino amination-Knoevenagel
condensation reaction to form 4aa.
Entry Solvent Temp (οC) Time (min) Yield (%)b
1 EtOH r.t. 40 65
2 DCM r.t. 60 50
3 MeOH r.t. 30 93
4 H2O 90 60 28
aReaction conditions: 1a (1.0 mmol, 1.0 equiv), 2a (1.0 mmol, 1.0 equiv), and
3a (2.5 mmol, 2.5 equiv) in solvent (2 mL) using open flask.
b Isolated yield.
Scheme 1. Scope of various cyclic secondary amines for the synthesis of 4a–d. Reagents and conditions: 1a (1.0 mmol, 1.0 equiv), 2a
(1.0 mmol, 1.0 equiv), and 3a–d (2.5 mmol, 2.5 equiv) in MeOH (2 mL) using open flask at room temperature under stirring conditions.
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Scheme 4. First, 1a underwent SNAr reaction with pyrro-
lidine (3a) through 1,4-addition/elimination pathway to
afford 5a that condensed with methyl cyanoacetate
(2a) to generate 4a. As an alternative strategy, Knoeve-
nagel product 6a was formed by pyrrolidine-catalyzed
condensation reaction between 1a and 2a. Hence, sub-
sequent SNAr reaction between 6a and 3a furnished 4a.
Besides methyl cyanoacetate (2a), ethyl nitroacetate
or cyanoacetic acid were used as a source of active
methylene in this reaction with pyrrolidine (3a) and
our substrate 1a. Under the optimized conditions, we
obtained a mixture of products that may be involved
amine salt and SNAr product 5a. Instead, we worked
on expanding the application of this approach to
involve malononitrile (2b) as a suitable starting material
for the Knoevenagel condensation. Hereupon, we used
the above-mentioned reaction conditions albeit with
one-pot, two-step domino strategy. First, base (1.0
equiv, 3a/3b)-catalyzed dimerization of malononitrile
(2.0 equiv, 2b) into non-isolated 2-amino-1,1,3-tricyano-
propene (7) [46] that has drawn tremendous attention of
interest due to its comprehensive implementations in
Scheme 2. Synthesis of 4e and 4f.
Scheme 3. Plausible reaction mechanism of the imidazole-catalyzed C–O bond formation in 4f.
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the synthesis of heterocyclic compounds that manifest
diverse biological and pharmaceutical properties [47].
At the same time, in another conical flask, suspension
solution of 4-(pyrrolidin-1-yl)-3-formylcoumarin (5a)/ 4-
(piperidin-1-yl)-3-formylcoumarin (5b) in MeOH (2 mL)
were prepared from direct amination of 1a (1.0 equiv)
and 3a/3b (1.5 equiv). Next, sequential addition of 7 to
5a/5b afforded the corresponding products 8a/8b in
excellent isolated yields (Scheme 5).
As delineated in Scheme 5, in contrast to the pub-
lished research paper by Angelova et al. [46] who
described the synthesis of aminium salt A and piperidi-
nium 5-amino-4-cyanochromeno[4,3,2-de]-1,6-
naphthyridine-1-carboxylate dihydrate (B) that con-
verted to the acidic form C via one-pot, one-step
cascade reaction of starting materials 1a, 2b, and 3b
as developed route to generate polyfunctionality substi-
tuted heterocyclic compounds with anticipated biologi-
cal performance. Herein, our chemistry proposal was
aimed to synthesize buta-1,3-diene-1,1,3-tricarbonitrile
derivatives 8a,b with potential anti-proliferative activity
and act as a key intermediate to construct privileged
molecules. Therefore, we developed a striped pathway
to achieve our target but, unfortunately, we failed to
expand the scope of this methodology to include
other bases such as 4-hydroxypiperidine (3c), morpho-
line (3d), and 4-AMP (3e), where the corresponding
methylene malononitrile derivatives 8c–e (8d [39])
were produced in high yields 88–98% (Figure 1). We pos-
tulate this contradiction is attributed to the difference in
basicity power between 3a,b and 3c–e.
Next, we turned our concern to confirm the amin-
ation occurs via 1,4-addition/elimination SNAr reaction
as a part of the mechanistic study (Scheme 4) and
control experiments. Earlier study by Yang et al. [48]
has been showed that the reaction between 3-chloro-
3-phenylacrylaldehyde 1b and 1,2,3,4-tetrahydroisoqui-
noline (THIQ, 3g) exhibited predominant product D
through Et3N-catalyzed 1,4-addition/elimination fol-
lowed by intramolecular cyclization process
(Scheme 6). In 2019, Vyasamudri and Yang [45] have
reported that condensation of 4-chloro-3-formylcou-
marin (1a) and THIQ (3g) using 4-dimethylaminopyri-
dine (DMAP) as an organic base afforded E in good
yield 78% and the reaction goes forward with 1,2-
addition/elimination then cyclization process through
removing of HCl. On the other hand, when Cs2CO3 was
utilized as the base, the reaction proceeds via 1,4-
addition/elimination then annulation fashion to furnish
F with moderate yield 53% (Scheme 6). In our manner,
the amination process of 1a and 3a,d,e passed
through Et3N-promoted1,4-addition/elimination at
room temperature in the open flask using MeOH to
supply 5a,d,e with high yields and the subsequent intra-
molecular cyclization did not take place. We likewise
sought to expand this fashion to include 4-chloro-3-
nitrocoumarin (1c) with 3a,d,e. The desired correspond-
ing amination products 9a,d,e were isolated in excellent
yields and shorter time. As produced in the above series,
we got the corresponding methoxy coumarin analogs 5f
and 9f when imidazole (3f) was utilized as a reactant
base (Scheme 6).
2.2. Biological evaluation
2.2.1. In vitro anti-proliferative activity
Anti-cervical cancer activity of all the synthesized com-
pounds was evaluated for their in vitro cytotoxicity
Scheme 4. Plausible reaction mechanism.
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Scheme 5. Previous work by Angelova group and synthesis of 8a,b.
Figure 1. Chemical structures of the prepared methylene malononitrile derivatives 8c–e.
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toward KB-3-1 cell line by resazurin-based assay [49] using
(+)-griseofulvin as a positive control. The results were
expressed as IC50 values that outlined in Table 2, Figure
2, and the values are an average ± SD of at least two separ-
ate experiments. Table 2 and Figure 2 show that the
domino amination-Knoevenagel product 4e that contain-
ing 4-AMP core displayed superior potency (IC50 = 15.5 ±
3.54 µM) than (+)-griseofulvin (IC50 = 19 ± 2.83 µM) while
8e is the closer one (IC50 = 21 ± 4.24 µM). The amination
products 5e and 9d showed moderately convergent
activity with IC50 > 70 µM. On the other hand, compounds
4c,d, 5d, 8d, and 9a indicated low activity with IC50 values
over than100 µM,whilstmolecules4a,b,4f,5a,f,8a–c, and
9e,f showed no activity against KB-3-1. The results mani-
fested that the presence of 4-AMP fragment was benefit
for the anti-cervical cancer activity.
Next, anti-proliferative potency of our synthesized
compounds was tested against A549 (non-small lung)
and PC3 (prostate) human cancer cell lines using also
resazurin-based cytotoxicity assay as reported by
Thorson research group [50–52] (Table 2, Figure 3).
Similar trend was detected with 4e (the most active)
against A549 (IC50 = 12.94 ± 1.51 µM), whilst 9d was
found to be the best toward PC3 (IC50 = 7.31 ±
Scheme 6. Previous work by Yang and Vyasamudri groups as well as scope of various cyclic secondary amines for the synthesis of 5a,
d–f and 9a,d–f. Reagents and conditions: 1a,c (1.0 mmol, 1.0 equiv), 3a,d–f (1.0 mmol, 1.0 equiv), and Et3N (1 mmol, 1 equiv) in MeOH
(2 mL) using open flask at room temperature under stirring conditions, R = CHO, 15 min, R = NO2, 5 min.
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0.48 µM). From overall cytotoxicity results, compound
8d that bearing malononitrile fragment and morpho-
lino unit showed selectivity against PC3 (IC50 = 20.16
± 0.07 µM), while 8e that embraced 4-AMP core
instead of morpholine ring was selective toward KB-
3-1 cell line. The remaining molecules pretended
with low cytotoxic effect. Grounded on these out-
comes, we concluded that the 4-AMP and morpholine
moieties would be the optimal cyclic secondary
amines in this study.
2.2.2. VEGFR-2 and EGFR inhibitory activity
Overexpression and/or hyperactivation of VEGFR-2 and
EGFR kinases are strongly associated with several malig-
nant cancers such as non-small cell lung carcinoma
(NSCLC), breast, ovarian, colon, and prostate cancers
[53]. Targeting one or both of them is a promising
pathway to explore more anti-angiogenic inhibitors
[54,55]. In the present study (Table 3), our examined
compounds; 4e, 5e, 8e, and 9d were more convenient
to VEGFR-2 than EGFR. They showed VEGFR-2 inhibitory
activities ranging from 24 to 88 nM while IC50 values
with EGFR were 32–165 nM. Figure 4 and Table 3
display remarkable inhibition potency toward VEGFR-2
by 8e (IC50 = 24.67 ± 1.1 nM) and 9d (IC50 =24.26 ±
1.1 nM). They are able to inactivate VEGFR-2 by 20%
enhancement (0.8-fold) over the standard sorafenib
(IC50= 31.08 ± 1.8 nM). Concerning the EGFR inhibitory
activity, the power of 8e was also comparable to the
standard erlotinib (1.2-fold). Among the tested com-
pounds, 9d recorded the lower inhibitory activity
against EGFR (IC50=165.00 ± 8.0 nM), confirming the
selectivity of 9d toward VEGFR-2.
The most potent one against KB-3-1 and A549 cell
lines (Table 2), 4e showed 1.2 and 2.5-fold inactivation
toward VEGFR-2 and EGFR, respectively. Moderate activi-
ties were also obtained by 5e against the examined
kinases. Regarding COVID-19, in silico studies have pre-
dicted higher affinity between the viral spike glyco-
protein (S) and the inhibitors of the hepatocyte growth
factor receptor (HGFR/c-MET), VEGFR and EGFR [56].
Consequently, exploring more agents against the
above receptors is more than welcome.
2.3. In silico studies
2.3.1. Physicochemical descriptors, drug-likeness,
and medicinal chemistry friendliness
In silico computational prediction represents a robust,
fast, and cost-effective approach to find new ligands
or drug leads as a part in drug discovery and develop-
ment strategy. Motivated by the aforementioned bio-
logical results and to explore the drug-likeness, lead-
likeness and biological target of the active molecules
(4e, 5e, 8d,e, and 9d), in silico studies using Swis-
sADME platform tools were effectuated [57]. To our
delight, the estimated compounds show the optimal
range for each physicochemical property where, the
molecular weight as an indication for the size par-
ameter is between 150 and 500 g/mol (MW, 276.24–
367.40), flexibility: no more than 9 rotatable bonds
(nROTB, 2-6), saturation: fraction of carbons in the
sp3 hybridization not less than 0.25 (Fraction Csp3,
0.31–0.38), except 8d is very close (Fraction Csp3 =
0.24), polarity: topological polar surface area is
between 20 and 130 Å2 (TPSA, 71.34–104.36) (Table 4).
Lipophilicity is a significant physicochemical par-
ameter quantified by the partition coefficient Log Po/w
between water and n-octanol that shows a good indi-
cator of permeability across the cell wall [58]. Our esti-
mated compounds manifested in XLOGP3 model Log
Po/w values between −0.7 and +5.0, ranging from 1.42
Table 2. IC50 (μM) of all the synthesized compounds against KB-





4a ─ >80 >80
4b ─ >80 >50
4c >100 >80 >50
4d >100 >80 >50
4e 15.5 ± 3.54 12.94 ± 1.51 11.28 ± 0.06
4f ─ >80 38.90*
5a ─ >80 >80
5d >100 >50 31.12*
5e >70 >80 >80
5f ─ >80 >80
8a ─ >80 >80
8b ─ >80 >80
8c ─ >80 >80
8d >100 >80 20.16 ± 0.07
8e 21 ± 4.24 >50 >50
9a >100 >80 >80
9d >70 19.78 ± 0.56 7.31 ± 0.48
9e ─ >80 >80
9f ─ NDc ND
(+)-Griseofulvin 19 ± 2.83 ND ND
DMSOd ─ ─ ─
aAnti-cervical cancer activity was done at Organic and Bioorganic Chemistry,
Faculty of Chemistry, Bielefeld University, Germany. IC50 values are the
mean ± SD of two independent determinations, (+)-griseofulvin was
used as positive control with IC50 = 19 ± 2.83 μM.
b Cytotoxicity IC50 values (mean ± SD of triplicate wells) against A549 (non-
small lung) and PC3 (prostate) human cancer cell lines were tested at the
Center for Pharmaceutical Research and Innovation, University of Ken-
tucky, Lexington, USA, and obtained after 72 h incubation. Actinomycin
D and H2O2 were used as positive control at 20 μM and 2 mM concen-
tration, respectively (0% viable cells) without dose–response curves (IC50
not determined) and just utilized to make sure the cytotoxic assay is
working [50–52].
cND, not determined.
dNegative control; 0.1% dimethyl sulphoxide was used as negative control
(100% live cells).
‘─’ Means no obvious inhibitory effect.
*Could not get +/− values due to the low toxicity.
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to 2.15, suggesting good permeability and absorption
through the cell membrane of infected cells. Moreover,
solubility is one pivotal property affecting the absorp-
tion and impacts many processes in drug development
activities such as handling and formulation [59]. Con-
cerning qualitative water solubility, all the predicted
molecules based on ESOL topological model are
soluble (Table 4).
In light of the above informative predictions, the esti-
mated compounds (4e, 5e, 8d,e, and 9d) passed all the
drug-likeness metrics (Lipinski, Ghose, Veber, Egan, and
Muegge) and have the same bioavailability score
(0.55). As a consequence, they could be possible drug
lead candidates. Regarding with medicinal chemistry
parameters, recognition of potentially problematic
fragments based on Pan Assay Interference Structures
(PAINS) shows zero alerts for all the predicted com-
pounds, confirming the safety and metabolic stability
of them. According to the rule of three (RO3), all com-
pounds are lead-likeness excepting compound 4e have
one violation for this rule (MW>350), therefore, 4e as a
lead hopping and potent compound will be subjected
to lead optimization and extra studies in the future. In
the quest for the biological target, we used SwissTar-
get-Prediction web tool to predict the most probable
targets of our bioactive small molecules (4e, 5e, 8d,e,
and 9d) [60]. The website performs target fishing using
ligand-based target prediction method that based on
the molecular similarity principle and the results are
shown in Figure 5.
Figure 2. Sigmoidal dose–response against KB-3-1 cell line; (A) 4e, (B) 5e, (C) 8e, (D) 9d, and (E) graph show the IC50 values of the
tested compounds 4e, 5e, 8e, 9d, and (+)-griseofulvin as a positive control.
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2.3.2. Docking study
The results that emanated from the biological evaluation
exhibit that 4e is the best in the cellular assay toward
cancerous cell lines and 8e is the most potent against
VEGFR-2 and EGFR in enzymatic assay as well as taking
in our account the biological target prediction (Figure
5) and the previous literatures [4,5,61,62], docking
study of 4e, 8e, and 9d against VEGFR-2 (KDR) and
EGFR receptor tyrosine kinases as targeted therapy was
implemented using iGEMDOCK program version 2.1
[63]. As a potent VEGFR-2 inhibitor, the crystal structure
of VEGFR-2 kinase domains in complex with N4-methyl-
N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxy-phe-
nyl)pyrimidine-2,4-diamine (three-letter code: KIM) (PDB
ID: 3CJG), manifests that the indazole moiety fit well into
the inside pocket of VEGFR-2. In the hinge region, the
pyrimidine N-1 and the C-2 anilino N–H were predicted
to make two significant hydrogen acceptor (2.86 Å)
and donor (2.71 Å) bonds with the peptide backbone
of Cys917, respectively (Figure 6A). Gefitinib (Iressa®) is
a selective inhibitor of EGFR tyrosine kinase and an
oral bioavailable drug utilized for certain breast, lung
and other cancers [6,64,65]. The docked pose of
gefitinib bound to EGFR (PDB ID: 4WKQ) shows that
the quinazoline ring occupies the same region as the
ATP purine ring (ATP-competitive inhibitor), and its
ring N-1 makes an important hydrogen bond with the
backbone nitrogen of Met793 (2.98 Å) (Figure 6B).
Thereafter, we docked 4e, 8e, and 9d with VEGFR-2
and EGFR binding sites to compare the docking pose
with co-crystallized ligands KIM and gefitinib, respect-
ively. Table 5 and Figure 6A demonstrate that com-
pound 4e is mostly overlapped with co-crystallized
Figure 3. (A) % Viability of A549 (non-small lung) and PC3 (prostate) human cancer cell lines (after 72 h) at 80 μM concentration of
compounds 4a–f, 5a, 5d–f, 8a–e, 9a, and 9d–e. (B) Dose–response of compounds 4e, 8e, and 9d against A549 (non-small cell lung)
human cancer cell line (72 h). (C) Dose–response of compounds 4d, 4e, 8d, 8e, and 9d against PC3 (prostate) human cancer cell line
(72 h).
Table 3. VEGFR-2 and EGFR inhibitory activities by compounds









4e 36.76 ± 1.8 1.2 67.09 ± 3.5 2.5
5e 88.08 ± 4.5 2.8 96.25 ± 4.7 3.6
8e 24.67 ± 1.1 0.8 31.60 ± 1.5 1.2
9d 24.26 ± 1.1 0.8 165.00 ± 8.0 6.2
Standard* 31.08 ± 1.8 1.0 26.79 ± 1.2 1.0
VEGFR-2, vascular endothelial growth factor receptor 2; EGFR, epidermal
growth factor receptor.
*The standard is the sorafenib as inhibitor to VEGFR-2 enzyme while it is the
erlotinib in the case of the EGFR.
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KIM into the binding site of VEGFR-2 by predicted fitness
(total energy) value of – 104.204 kcal/mol comparable to
KIM with the fitness value of −102.401 kcal/mol. Also, 4e
docking mode with binding pocket of VEGFR-2 pro-
duced two conventional H-bonds, one among them in
the hinge region between donor NH-1 of 4-AMP unit
and carbonyl oxygen of the key amino acid residue
Cys917 (2.60 Å), while the second one is observed
between C-2 oxygen of coumarin moiety and peptide
backbone of Asp1044 (2.73 Å) as a part of the DFG
cavity. Consequently, these interactions proving the
importance of 4-AMP and coumarin fragments in 4e.
As amply illustrated in Figure 6B, 4e is overlapped
with gefitinib in the active binding site of EGFR (PDB
ID: 4WKQ) by the fitness value of −112.020 kcal/mol
comparable to gefitinib with the fitness value of
Figure 4. IC50 of compounds 4e, 5e, 8e, and 9d as inhibitors to the VEGFR-2 and EGFR human kinases. Sorafenib is the standard
inhibitor to VEGFR-2 enzyme, while erlotinib is the equivalent in the case of the EGFR.
Table 4. Physicochemical properties, drug-likeness, and medicinal chemistry parameters of compounds 4e, 5e, 8d,e, and 9d.
Predictive models and their parameters
Compounds
4e 5e 8d 8e 9d
MW (g/mol) 367.40 286.33 307.30 334.37 276.24
nROTBa (≠) 6 4 2 4 2
Fraction Csp3 0.35 0.38 0.24 0.32 0.31
HBAb (≠) 6 4 6 5 5
HBDc (≠) 2 2 0 2 0
MRd 105.97 85.81 87.41 99.63 77.03




2.14 2.15 1.46 2.01 1.42
WLOGP 1.60 1.45 1.57 1.95 1.16
MLOGP 1.18 1.20 0.47 0.94 0.37
Log Sg (ESOL) −3.34 −3.06 −2.85 −3.21 −2.69
Quantitative solubility (mg/mL) 1.66e−01 2.50e−01 4.29e−01 2.06e−01 5.70e−01
Qualitative solubility Soluble Soluble Soluble Soluble Soluble
Lipinski (Pfizer filter, RO5)h Yes Yes Yes Yes Yes
Ghosei (Amgen filter) Yes Yes Yes Yes Yes
Veberj (GSK filter) Yes Yes Yes Yes Yes
Egank (Pharmacia filter) Yes Yes Yes Yes Yes
Mueggel (Bayer filter) Yes Yes Yes Yes Yes
Bioavailability score 0.55 0.55 0.55 0.55 0.55
PAINS 0 alert 0 alert 0 alert 0 alert 0 alert
Lead-likeness (RO3)m No; 1 violation: MW>350 Yes Yes Yes Yes
Target prediction Kinase 73.3% Kinase 53.3% Kinase 26.7% Nuclear receptor 20.0% Protease 33.3%
anROTB, no. of rotatable bonds.
bHBA, hydrogen bond acceptor.
cHBD, hydrogen bond donor.
dMR, molar refractivity.
eTPSA, topological polar surface area.
fLog Po/w, the partition coefficient between n-octanol and water.
gLog S, the decimal logarithm of the molar solubility in water.
hLipinski (RO5) criteria range are: lipophilicity (Log Po/w)≤ 5, MW≤ 500, H-bond donors≤ 5, and H-bond acceptors≤ 10.
iGhose filter criteria range are: Log Po/w in −0.4 to +5.6 range, MR from 40 to 130, MW from 180 to 480, no. of atoms from 20 to 70.
jVeber rule criteria range are: RB≤ 10 and TPSA≤ 140 Å2.
kEgan rule criteria range are: WLOGP≤ 5.88, TPSA≤ 131.6 Å2.
lMuegge rule criteria range are: 200≤MW≤ 600, −2≤ XLOGP3≤ 5, TPSA = 150 Å2, no. of rings≤ 7, no. of heteroatoms > 1, nROTB≤ 15, HBA≤ 10, HBD≤ 5.
mRO3 criteria range are: XLOGP3≤ 3.5, MW≤ 350, H-bond donors≤ 3, H-bond acceptors≤ 3, and RB≤ 3 [57].
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−104.299 kcal/mol (Table 5). Analysis of 4e docking
mode in the binding pocket of EGFR shows two conven-
tional H-bonds. In the same manner, NH-1 of 4-AMP core
is stabilized by hydrogen bond with the carbonyl oxygen
of the key amino acid residue Met793 (2.61 Å) in the
hinge region. The second one is generated between
cyano nitrogen (CN) in the side chain as a proton accep-
tor and the distal NH2 of Lys745 (3.22 Å). Moreover, the
coumarin moiety inserts into a hydrophobic pocket.
Like 4e, NH-1 of 4-AMP fragment in compound 8e
interacts with Cys917 (3.35 Å) in the binding cavity of
VEGFR-2 (−100.502 kcal/mol) and Met793 (2.69 Å) in
EGFR (−113.558 kcal/mol) via hydrogen bonding. At
the same time, coumarin moiety plays an important
role for interaction stabilizing between 8e and kinases,
where its carbonyl oxygen forms H-bond with Phe1045
(3.18 Å) in VEGFR-2 and O-1 act as a proton acceptor
from Thr854 (3.08 Å) in EGFR (Figure 6C and D).
Figure 5. Ligand-based target prediction by SwissTarget-Prediction web tool; (A) 4e, (B) 5e, (C) 8d, (D) 8e, and (E) 9d.
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The binding mode of compound 9d against VEGFR-2
(Figure 6E) and EGFR (Figure 6F) explains why 9d was a
selective and highly potent nanomolar inhibitor of
VEGFR-2 with the IC50 value of 24.26 ± 1.1 nM (Table 3).
Figure 6E shows that 9d was overlapped with co-crystal-
lized ligand KIM via coumarin unit only and the nitro
group fit into the outside pocket of VEGFR-2. Thus, car-
bonyl coumarin and nitro group as hydrogen acceptors
were predicted to form new four H-bonds with amino
acid residues Lys866, Phe1045, and Gly1046. Note-
worthy, 9d did not form the foremost H-bond with
Cys917, confirming the importance of 4-AMP unit and
Figure 6. (A, C, E and G) Three-dimensional docking poses of 4e, 8e, 9d, and sorafenib (cyan), respectively, with KIM (grey) within the
binding site of VEGFR-2 (PDB ID: 3CJG). (B, D, F and H) Three-dimensional binding modes of 4e, 8e, 9d, and erlotinib (cyan), respect-
ively, with gefitinib (grey) within the active site of EGFR (PDB ID: 4WKQ). H-bonds are denoted by dashed lines in green. All pictures
were prepared with Discovery Studio Visualizer Client 2020, and are simple for clarity of presentation.
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establishing a new pathway to suppress VEGFR-2. On the
contrary, Figure 6F displays that 9d did not overlap with
gefitinib within the binding site of EGFR, thus, this inter-
action pattern dramatically decreases the activity of 9d
toward EGFR kinase (IC50= 165.00 ± 8.0 nM).
Finally, the docking modes of sorafenib and erlotinib
as the reference drugs in VEGFR-2 and EGFR inhibitory
activity assay, respectively, were predicted (Table 5,
Figure 6G,H). Sorafenib and erlotinib demonstrated
high binding affinity toward VEGFR-2 and EGFR, respect-
ively, as well displayed the major H-bonds in the hinge
region with the key amino acid residues Cys917 and
Met793, respectively, as generated with our compounds
binding modes.
2.4. Structure–activity relationship
As stated above in the biological evaluation and pre-
dicted docking modes of compounds 4e, 8e, and 9d,
structure–activity relationship (SAR) study on the cyclic
secondary amine fragment shows that 4-AMP and mor-
pholine units are the optimal for cellular and enzymatic
potencies. Compound 4e with 4-AMP and methyl cya-
noacrylate cores has good anti-proliferative activity
toward all the three tumor cell lines and more active
against VEGFR-2 than EGFR. When methyl cyanoacrylate
fragment is replaced by malononitrile and 4-AMP is
retained, the generated compound 8e is selective
toward KB-3-1 and a promising dual inhibitor VEGFR-2
and EGFR. Compound 9d with morpholine and nitro
groups is effective against A549 and PC3 cell lines, but
selective inhibitor of VEGFR-2 (IC50=24.26 ± 1.1 nM) in
comparison with EGFR (IC50= 165.00 ± 8.0 nM). When
3-NO2 group in 9d is changed by methylene malononi-
trile unit, the corresponding compound 8d is selective
toward PC3 cell line (Table 2). It should be noted that,
when methylene malononitrile unit in 8e is substituted
by formyl group, the obtained small molecule 5e
showed lower inhibitory activity against VEGFR-2 and
EGFR kinases (Table 3).
In cellular anti-proliferative assay, a big drop-in
activity is detected when 4-AMP and morpholine units
are replaced with other amines. As illustrated by the
docking study, coumarin framework is an important for
potent activity, where it forms H-bonds and suitable to
occupy the hydrophobic pocket, thereby improving
the binding affinity of the hit molecules to the thera-
peutic targets. Through the inclusive valuation, cyclic
secondary amines including 4-AMP and morpholine
are crucial for maintaining the potency of the target
small molecules in our study. As well side chain frag-
ments encompassing methyl cyanoacetate, malononi-
trile and nitro group have an obviously impact on
cellular and enzymatic activities. Coumarin system can
be considered good bioisostere of quinazoline scaffold
to discovery and development of EGFR potent inhibitors.
These finding tell us the useful pathway to create a
rational design using extension tactics in order to
achieve the optimal binding interactions, hence get
more potent VEGFR-2 and EGFR inhibitors (Figure 7).
3. Materials and methods
3.1. Materials and instruments
Melting points were determined on a BÜCHI Melting
Point B-540 apparatus in open capillaries and are uncor-
rected (BÜCHI Germany). NMR spectra (1H NMR and 13C
NMR) were recorded on Bruker Avance DRX 500HD MHz
(1H: 500 MHz, 13C: 125 MHz) spectrometer (Bruker, USA)
at 298 K. Tetramethylsilane (TMS) is used for internal cali-
bration (1H NMR and 13C NMR: 0.00 ppm). Chemical
shifts were reported in parts per million (ppm) on the
δ scale and relative to residual solvent peaks (DMSO-
d6:
1H: 2.50 ppm, 13C: 39.5 ppm). Coupling constants
(J ) are reported in Hz with the following abbreviations
used to indicate splitting: s = singlet, d = doublet, t =
triplet, q = quartet, m =multiplet, br = broad signal. ESI
mass spectra were recorded using an ion trap mass spec-
trometer equipped with a standard ESI/APCI source.
Samples were introduced by direct infusion with a
syringe pump. Nitrogen served both as the nebulizer
gas and the dry gas. Nitrogen was generated by a nitro-
gen generator. Helium served as cooling gas for the ion
trap and collision gas for MSn experiments (Bruker Dalto-
nik GmbH, Bremen, Germany). Starting materials and
reagents were obtained from commercial sources and
used without further purification, unless otherwise indi-
cated. Solvents were dried and purified following stan-
dard procedures in organic chemistry. The purity of
the synthesized compounds was investigated by TLC,
performed on Merck precoated silica gel 60 F254 alumi-
num sheets with a solvent mixture of DCM-MeOH (98-
2) as eluent. Spots were visualized under UV illumination
at 254 and 366 nm.
Table 5. Binding fitness and no. of H-bonds of 4e, 8e, and 9d to
VEGFR-2 and EGFR in comparison with KIM, sorafenib, gefitinib,
and erlotinib as the reference drugs.
Compounds
Fitness (kcal/mol) H-bonds (≠)
VEGFR-2 EGFR VEGFR-2 EGFR
4e −104.204 −112.020 2 2
8e −100.502 −113.558 2 2
9d −89.051 −94.544 4 2
KIM −102.401 ─ 2 ─
Sorafenib −107.572 ─ 5 ─
Gefitinib ─ −104.299 ─ 1
Erlotinib ─ −102.323 ─ 3
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3.2. Synthesis and characterization
3.2.1. Synthesis of 4-chloro-3-formylcoumarin (1a)
Our substrate 1a was synthesized from 4-hydroxycou-
marin according to the Vilsmeier–Haack protocol [36].
3.2.2. General procedure for the synthesis of
methyl (E)-2-cyano-3-(4-
substitutedcoumarinyl)acrylates 4a–f
Methyl cyanoacetate (2a, 1 mmol) was treated with 4-
chloro-3-formylcoumarin (1a, 1.0 mmol) and cyclic sec-
ondary amines (3a–f, 2.5 mmol) in MeOH (2 mL). Using
the open flask, the mixture was stirred at room tempera-
ture for 30-45 min. After the reaction was completed
(TLC), the solvent was removed under reduced pressure
and the crude product was purified by simple recrystal-




Yield 93%; yellow solid; mp 230−232 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.44 (s, 1H), 8.04 (dd, J = 8.1,
1.5 Hz, 1H), 7.67 (ddd, J = 8.5, 7.3, 1.4 Hz, 1H), 7.43–7.36
(m, 2H), 3.77 (s, 3H), 3.34–3.33 (m, 4H, overlapped with
water of DMSO), 2.05–2.01 (m, 4H); 13C NMR (125 MHz,
DMSO-d6) δ 164.7 (C4─N), 161.6 (C = O ester), 158.7 (C
= O lactone), 151.5 (C─O lactone), 151.1 (CH olefinic),
133.2, 126.7, 124.1, 118.6, 117.7, 116.5, 93.9, 90.1, 56.1
(OCH3), 52.8 (2CH2N), 25.0 (2CH2); (+)-ESI-MS, m/z (%):




Yield 91%; faint orange solid; mp 192−194 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.17 (s, 1H), 7.93 (dd, J = 8.2, 1.5 Hz,
1H), 7.70 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.44–7.38 (m, 2H),
3.85 (s, 3H), 3.68–3.64 (m, 4H), 1.77–1.73 (m, 6H); 13C
NMR (125 MHz, DMSO-d6) δ 163.5 (C4─N), 163.1 (C = O
ester), 158.9 (C = O lactone), 153.4 (C─O lactone), 152.5
(CH olefinic), 134.0, 127.3, 124.6, 118.0, 117.5, 115.8,
102.8, 100.9, 54.8 (2CH2N), 53.5 (OCH3), 27.0 (2CH2), 23.6
(CH2); (+)-ESI-MS, m/z (%): 361 [M + Na]
+ (100), 699 [2M
+Na]+ (6). See Supporting Information, Figs. S4–S6.
Methyl (E)-2-cyano-3-(4-(4-hydroxypiperidin-1-yl)-2-
oxo-2H-chromen-3-yl)acrylate (4c)
Yield 96%; orange solid; mp 194−196 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.92 (dd, J = 8.2,
1.6 Hz, 1H), 7.70 (ddd, J = 8.4, 7.2, 1.4 Hz, 1H), 7.44–7.38
(m, 2H), 4.97 (d, J = 3.7 Hz, 1H, OH), 3.89 (dq, J = 7.8,
3.8 Hz, 1H), 3.85 (s, 3H, OCH3), 3.81 (ddd, J = 12.7, 6.3,
3.0 Hz, 2H), 3.58 (ddd, J = 12.7, 8.6, 3.3 Hz, 2H), 2.00–
1.93 (m, 2H), 1.69–1.60 (m, 2H); 13C NMR (125 MHz,
Figure 7. The SAR study of the synthesized compounds.
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DMSO-d6) δ 163.5 (C4─N), 162.9 (C = O ester), 158.9 (C =
O lactone), 153.3 (C─O lactone), 152.5 (CH olefinic),
134.0, 127.2, 124.6, 118.0, 117.5, 115.8, 102.8, 100.9,
64.7 (CHOH), 53.5 (OCH3), 51.2 (2CH2N), 35.4 (2CH2);
(+)-ESI-MS, m/z (%): 377 [M + Na]+ (100), 731 [2M + Na]+
(12). See Supporting Information, Figs. S7–S9.
Methyl (E)-2-cyano-3-(4-morpholino-2-oxo-2H-
chromen-3-yl)acrylate (4d)
Yield 92%; yellow solid; mp 218−220 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.19 (s, 1H), 7.95 (dd, J = 8.3,
1.5 Hz, 1H), 7.71 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.45 (dd,
J = 8.3, 1.2 Hz, 1H), 7.40 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H),
3.86 (s, 3H), 3.82 (t, J = 4.6 Hz, 4H), 3.72 (t, J = 5.5,
3.7 Hz, 4H); 13C NMR (125 MHz, DMSO-d6) δ 163.4
(C4─N), 162.4 (C = O ester), 158.8 (C = O lactone), 153.4
(C─O lactone), 151.9 (CH olefinic), 134.1, 127.3, 124.7,
118.0, 117.1, 115.7, 103.8, 101.3, 67.22 (2CH2O), 53.7
(2CH2N), 53.5 (OCH3); (+)-ESI-MS, m/z (%): 363 [M +




Yield 96%; yellow solid; mp 172−174 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.76 (t, J = 5.8 Hz, 1H), 8.64 (s,
1H), 8.34 (dd, J = 7.9, 1.7 Hz, 1H), 7.68 (ddd, J = 8.6, 7.3,
1.7 Hz, 1H), 7.44 (td, J = 7.6, 1.1 Hz, 1H), 7.39 (dd, J = 8.2,
1.0 Hz, 1H), 3.90 (s, 3H), 3.59 (t, J = 6.2 Hz, 2H), 2.95 (dt,
J = 12.1, 3.4 Hz, 2H), 2.44 (td, J = 12.0, 2.5 Hz, 2H), 1.82–
1.72 (m, 2H), 1.66 (dd, J = 12.6, 3.5 Hz, 2H), 1.23–1.17 (m,
1H), 1.17–1.12 (m, 1H); 13C NMR (125 MHz, DMSO-d6) δ
166.5 (C4─NH), 160.1 (C=O ester), 159.71 (C=O lactone),
155.0 (C─O lactone), 153.9 (CH olefinic), 142.1, 133.8,
125.25, 125.17, 118.8, 117.5, 107.8, 105.8, 53.0 (OCH3),
47.1 (CH2NH), 46.3 (2CH2NH), 36.7 (CH aliphatic), 31.3
(2CH2); (+)-ESI-MS, m/z (%): 368 [M +H]
+ (100), 735 [2M
+ H]+ (6). See Supporting Information, Figs. S13–S15.
Methyl (E)-2-cyano-3-(4-methoxy-2-oxo-2H-chromen-
3-yl)acrylate (4f)
Yield 89%; yellow solid; mp 148−150 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.97 (dd, J = 8.0,
1.6 Hz, 1H), 7.78 (ddd, J = 8.7, 7.2, 1.6 Hz, 1H), 7.49 (dd,
J = 8.4, 1.1 Hz, 1H), 7.46 (ddd, J = 8.3, 7.3, 1.1 Hz, 1H),
4.13 (s, 3H), 3.89 (s, 3H); 13C NMR (125 MHz, DMSO-d6)
δ 167.2, 162.0, 159.9, 150.5, 149.3, 133.2, 126.2, 125.1,
117.9, 117.2, 116.7, 103.9, 99.2, 63.8, 52.3; (+)-ESI-MS,
m/z (%): 308 [M + Na]+ (100), 593 [2M + Na]+ (22). See
Supporting Information, Figs. S16–S18.
3.2.3. General procedure for the synthesis of buta-
1,3-diene-1,1,3-tricarbonitrile derivatives 8a,b and
methylene malononitrile analogs 8c–e
Using open flask, a solution of malononitrile (2b,
2 mmol) and cyclic secondary amines (3a–e, 1 mmol)
in MeOH (2 mL) was stirred at room temperature for
10 min. At the same time, anther mixture of 4-chloro-
3-formylcoumarin (1a, 1.0 mmol) and the same cyclic
secondary amines (3a–e, 1.5 mmol) in MeOH (2 mL)
was also produced by stirring at ambient temperature
for 10 min. Next, the two mixtures were combined
together and sequential stirring was continued at
room temperature until a new product was formed
(TLC). Hence, the solvent was removed under reduced
pressure using the rotary evaporator and the crude
product was purified by simple recrystallization




Yield 97%; yellow solid; mp > 320 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.72 (s, 1H), 7.85 (dd, J = 8.2,
1.5 Hz, 1H), 7.73 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.63 (s,
2H), 7.56 (dd, J = 8.4, 1.3 Hz, 1H), 7.45 (ddd, J = 8.3, 7.2,
1.3 Hz, 1H), 3.72–3.58 (m, 2H), 3.29–2.95 (m, 2H), 1.97–
1.86 (m, 2H), 1.86–1.62 (m, 2H); 13C NMR (125 MHz,
DMSO-d6) δ 166.51(C─NH2), 161.8 (C4─N), 159.5, 155.9,
155.3, 152.4, 134.0, 133.5, 126.1, 125.9, 120.6, 118.9,
116.7, 116.6, 103.7, 76.4, 48.1, 46.1, 25.9, 24.6; (+)-ESI-
MS, m/z(%): 737 [2M + Na]+ (90), 1094 [3M + Na]+ (2).
See Supporting Information, Figs. S19–S21.
(Z )-2-amino-4-(2-oxo-4-(piperidin-1-yl)-2H-chromen-
3-yl)buta-1,3-diene-1,1,3-tricarbonitrile (8b)
Yield 94%; yellow solid; mp 308−310 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.92 (dd, J = 8.3,
1.5 Hz, 1H), 7.73 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.65–7.60
(m, 2H), 7.56 (dd, J = 8.4, 1.2 Hz, 1H), 7.46 (ddd, J = 8.3,
7.1, 1.3 Hz, 1H), 3.84–3.73 (m, 2H), 3.30–3.21 (m, 1H),
3.21–3.13 (m, 1H), 1.69–1.58 (m, 4H), 1.46–1.36 (m, 1H),
1.26–1.16 (m, 1H); 13C NMR (125 MHz, DMSO-d6) δ
166.8, 161.7, 159.5, 155.9, 155.0, 152.4, 134.0, 133.9,
126.5, 125.8, 119.6, 118.9, 116.7, 116.5, 103.9, 76.3, 47.8,
26.3, 24.4; (+)-ESI-MS m/z (%): 372 [M+ H]+. See Support-
ing Information, Figs. S22–S24.
2-((4-(4-Hydroxypiperidin-1-yl)-2-oxo-2H-chromen-3-
yl)methylene)malononitrile (8c)
Yield 88%; yellow solid; mp 294−296 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.97 (dd, J = 8.3, 1.5 Hz, 1H),
8.76 (s, 1H), 7.81 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.53
(ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.47 (dd, J = 8.4, 1.3 Hz,
1H), 5.77–5.76 (m, 2H), 3.18–3.17 (m, 4H), 2.10–2.09 (m,
4H); 13C NMR (125 MHz, DMSO-d6) δ 161.9, 158.4,
153.3, 148.7, 147.9, 135.8, 126.0, 125.6, 118.9, 117.3,
115.0, 103.0, 93.5, 55.4, 49.1, 31.2; (+)-ESI-MS, m/z (%):
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Yield 96%; yellow solid; mp 196−198 °C; (from litera-
ture [39], yield 52%; orange solid, mp 193−195 °C).




Yield 98%; yellow solid; mp 154−156 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.32 (dd, J = 7.9,
1.7 Hz, 1H), 7.69 (ddd, J = 8.7, 7.4, 1.8 Hz, 2H), 7.48–7.43
(m, 1H), 7.40 (d, J = 8.3 Hz, 1H), 3.51 (d, J = 6.7 Hz, 2H),
2.98 (dt, J = 12.4, 3.3 Hz, 2H), 2.50–2.43 (m, 2H), 1.89–
1.81 (m, 1H), 1.71–1.63 (m, 3H), 1.23–1.11 (m, 2H); 13C
NMR (125 MHz, DMSO-d6) δ 159.6, 159.4, 154.5, 153.8,
145.4, 134.0, 125.3, 118.7, 117.5, 116.6, 115.9, 106.2,
93.4, 47.5, 46.0, 36.2, 30.8; (+)-ESI-MS, m/z (%): 335 [M
+ H]+ (100), 669 [2M + H]+ (1). See Supporting Infor-
mation, Figs. S29–S31.
3.2.4. General procedure for the synthesis of 4-
substituted-3-formyl/nitro-2H-chromen-2-ones 5a,
d–f and 9a,d–f
Cyclic secondary amines (3a,d–f, 1 mmol) was added to
a stirred solution of 4-chloro-3-formyl/nitrocoumarin
(1a,c, 1.0 mmol) and triethylamine (Et3N, 1 mmol) in
MeOH (2 mL). The reaction mixture was stirred at room
temperature for 5–15 min. After the reaction was com-
pleted (TLC), the solvent was removed under reduced
pressure and the crude product was purified by simple
recrystallization (MeOH) or washing with hot methanol
to afford the desired compound.
4-Pyrrolidino-3-formyl-2H-chromen-2-one (5a)
Yield 93%; white solid; mp 190−192 °C; 1H NMR
(500 MHz, DMSO-d6) δ 9.67 (s, 1H), 8.06 (dd, J = 8.1,
1.5 Hz, 1H), 7.63 (ddd, J = 8.5, 7.3, 1.4 Hz, 1H), 7.36 (dd,
J = 8.3, 1.2 Hz, 1H), 7.33 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H),
3.85 (s, 4H), 1.99–1.93 (m, 4H); 13C NMR (125 MHz,
DMSO-d6) δ 183.4 (CHO), 163.7 (C4─N), 158.0 (C=O
lactone), 152.2 (C─O lactone), 133.0, 127.9, 123.5,
118.1, 117.5, 97.4, 56.7 (2CH2N), 24.9 (2CH2); (+)-ESI-MS,
m/z (%): 266 [M+ Na+ (100), 509 [2M + Na]+ (35). See Sup-
porting Information, Figs. S32–S34.
4-Morpholino-3-formyl-2H-chromen-2-one (5d)
Yield 95%; yellow solid; mp 150−152 °C; 1H NMR
(500 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.99 (dd, J = 8.2,
1.5 Hz, 1H), 7.69 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.41 (dd,
J = 8.4, 1.3 Hz, 1H), 7.37 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H),
3.90–3.86 (m, 4H), 3.65 (t, J = 4.7 Hz, 4H); 13C NMR
(125 MHz, DMSO-d6) δ 186.5 (CHO), 176.5 (C4─N),
162.5 (C=O lactone), 154.4 (C─O lactone), 134.3, 126.3,
124.1, 121.3, 117.0, 95.3, 66.8 (2CH2O), 54.5 (2CH2N);
(+)-ESI-MS, m/z(%): 282 [M + Na]+ (35), 541 [2M + Na]+
(100). See Supporting Information, Figs. S35–S37.
4-((Piperidin-4-ylmethyl)amino)-3-formyl-2H-
chromen-2-one (5e)
Yield 85%; yellow solid; mp 208−210 °C; 1H NMR
(500 MHz, DMSO-d6) δ 11.94 (t, J = 5.1 Hz, 1H, NHAr),
9.94 (s, 1H), 8.28 (d, J = 8.2 Hz, 1H), 7.78 (t, J = 7.8 Hz,
1H), 7.46–7.39 (m, 2H), 3.91 (t, J = 5.9 Hz, 2H), 3.33–3.23
(m, 3H), 2.90 (td, J = 12.8, 2.9 Hz, 2H), 2.04 (ttt, J = 10.4,
6.6, 3.4 Hz, 1H), 1.95 (d, J = 13.7 Hz, 2H), 1.58–1.44 (m,
2H); 13C NMR (125 MHz, DMSO-d6) δ 191.0 (CHO), 162.2
(C4─NH), 159.9 (C=O lactone), 155.2 (C─O lactone),
135.6, 129.3, 124.6, 118.5, 114.0, 96.3, 52.2 (CH2NH), 43.1
(2CH2NH), 34.6 (CH), 26.7 (2CH2); (+)-ESI-MS, m/z (%):
287 [M+ H]+. See Supporting Information, Figs. S38–S40.
4-Methoxy-3-formyl-2H-chromen-2-one (5f)
Yield 89%; pale yellow solid; mp 118−120 °C; 1H NMR
(500 MHz, DMSO-d6) δ 10.12 (s, 1H), 7.99 (dd, J = 8.0,
1.6 Hz, 1H), 7.79 (ddd, J = 8.7, 7.2, 1.6 Hz, 1H), 7.48–7.41
(m, 2H), 4.19 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ
189.2 (CHO), 170.0 (C4─O), 162.3 (C=O lactone), 153.6
(C─O lactone), 135.5, 125.8, 125.4, 117.3, 117.1, 106.7,
65.6 (OCH3); (+)-ESI-MS, m/z(%): 227 [M +Na]
+ (100), 431
[2M+Na]+ (7)+. See Supporting Information, Figs. S41–S43.
4-Pyrrolidino-3-nitro-2H-chromen-2-one (9a)
Yield 97%; yellow solid; mp 204−206 °C; 1H NMR
(500 MHz, DMSO-d6) δ 8.18 (dd, J = 8.1, 1.4 Hz, 1H),
7.69 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.41–7.36 (m, 2H),
3.83–3.77 (m, 4H), 2.01–1.95 (m, 4H); 13C NMR
(125 MHz, DMSO-d6) δ 155.2 (C4─N), 154.4 (C=O
lactone), 151.2 (C─O lactone), 133.6, 128.1, 123.8,
117.6, 117.0, 114.6, 55.6 (2 CH2N), 24.7 (2CH2); (+)-ESI-
MS, m/z(%): 283 [M+ Na]+ (100), 543 [2M + Na]+ (17).
See Supporting Information, Figs. S44–S46.
4-Morpholino-3-nitro-2H-chromen-2-one (9d)
Yield 96%; yellow solid; mp 210−212 °C; 1H NMR
(500 MHz, DMSO-d6) δ 7.90 (dd, J = 8.1, 1.5 Hz, 1H),
7.76 (ddd, J = 8.6, 7.2, 1.5 Hz, 1H), 7.50–7.45 (m, 2H),
3.88–3.83 (m, 4H), 3.39–3.33 (m, 4H); 13C NMR
(125 MHz, DMSO-d6) δ 155.5 (C4─N), 153.1 (C=O
lactone), 152.5 (C─O lactone), 134.6, 127.7, 125.8,
125.5, 118.1, 116.1, 66.2 (2 CH2O), 51.5 (2 CH2N);
(+)-ESI-MS, m/z (%): 299 [M+ Na]+ (100), 575 [2M+ Na]+
(25). See Supporting Information, Figs. S47–S49.
4-((Piperidin-4-ylmethyl)amino)-3-nitro-2H-chromen-
2-one (9e)
Yield 89%; yellow solid; mp 208−210 °C; 1H NMR
(500 MHz, DMSO-d6) δ 15.82 (s, 1H, NHAr), 7.22–7.18 (m,
2H), 6.78–6.75 (m, 1H), 6.69 (td, J= 7.5, 1.2 Hz, 1H), 3.32 (d,
J= 6.5 Hz, 2H), 3.28 (dt, J = 12.4, 3.4 Hz, 3H), 2.88 (td, J=
12.8, 3.0 Hz, 2H), 1.98–1.88 (m, 1H), 1.84 (d, J= 14.6 Hz,
2H), 1.36 (qd, J = 12.5, 4.0 Hz, 2H); 13C NMR (125 MHz,
DMSO-d6) δ 170.0, 163.4, 162.0, 131.7, 130.0, 120.4, 117.6,
117.3, 103.3, 55.7, 49.9, 43.7, 34.5, 27.5; (+)-ESI-MS,m/z (%):
304 [M+ H]+. See Supporting Information, Figs. S50–S52.
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4-Methoxy-3-nitro-2H-chromen-2-one (9f)
Yield 91%; white solid; mp 110−112 °C; 1H NMR
(500 MHz, DMSO-d6) δ 7.98 (dd, J = 8.1, 1.6 Hz, 1H),
7.82 (ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.55–7.48 (m, 2H),
4.18 (s, 3H), 13C NMR (125 MHz, DMSO-d6) δ 167.8
(C4─O), 158.7 (C=O lactone), 151.7 (C─O lactone),
135.4, 125.5, 123.4, 117.3, 116.5, 115.5, 60.7 (OCH3);
(+)-ESI-MS, m/z (%): 244 [M+ Na]+ (100), 465 [2M+ Na]+
(6). See Supporting Information, Figs. S53–S55.
3.3. Resazurin cellular-based bioassay
Anti-cervical cancer activity of all the synthesized com-
pounds were evaluated for the in vitro cytotoxicity
toward KB-3-1 cell line (was obtained from the American
Type Culture Collection, ATCC, Rockville, MD, USA) by
resazurin-based assay [49] using (+)-griseofulvin as a
positive control. Next, anti-proliferative potency of our
synthesized compounds was tested against A549 (non-
small lung) and PC3 (prostate) human cancer cell lines
using the same assay as reported by Thorson research
group [50–52].
3.4. Enzyme inhibitory bioassay
In the case of the VEGFR-2 enzymatic assay, we followed
the instruction manual of VEGFR-2 (KDR) Kinase Assay Kit
Catalog # 40325. On the other hand, EGFR Kinase Assay Ki
Catalog # 40321 was followed to examine the capability
of the selected compounds to inactivate the enzyme
EGFR kinase. A series of 10-fold dilutions was prepared
from each compound (4e, 5e, 8e, and 9d) while sorafenib
(Cat no.284461-73-0, Santa Cruz) and erlotinib (Cat
no.183321-74-6, Cayman) were matched as the positive
controls in synchronize to VEGFR-2 and EGFR assays,
respectively. At the end of the experiment, the lumines-
cence was measured by Tecan spark microplate reader.
The compounds concentration that inactivate 50% of
the measured kinases was separately, calculated using a
curve fitting software; Prism, version 6.
3.5. In silico computational predictions
3.5.1. Physicochemical descriptors, drug-likeness,
and medicinal chemistry parameters
The physicochemical properties of compounds 4e, 5e,
8d,e, and 9d were predicted using SwissADME [57] as
formerly described (Table 4).
3.5.2. Biological target prediction
The biomolecular target of compounds 4e, 5e, 8d,e, and
9d were estimated through the SwissTarget-Prediction
web tool [60] that using ligand-based target prediction
approach which based on the molecular similarity prin-
ciple (Table 4, Figure 5).
3.5.3. Molecular docking simulation
In silico flexible ligand docking study has been per-
formed by iGEMDOCK program version 2.1 (Department
of Biological Science and Technology & Institute of Bioin-
formatics, National Chiao Tung University, Taiwan) [63]
that uses a generic evolutionary approach (GA) and an
empirical scoring function to explore the interaction
modes between the hit molecules (4e, 8e, and 9d) and
VEGFR-2/KDR (PDB ID: 3CJG) and EGFR (PDB ID: 4WKQ)
as a biological targets. Firstly, the three-dimensional
(3D) structures of VEGFR-2 with KIM complex and EGFR
with gefitinib were obtained from RCSB Protein Data
Bank (https://www.rcsb.org) and the co-crystallized
ligand, was extracted and docked back to the corre-
sponding binding site, to define the ability of docking
protocol to reproduce the docking mode of the inhibitor
observed in the crystal structure (iGEMDOCK validation)
(Figure 8).
Secondly, the two-dimensional (2D) structure of hit
compounds were drawn by ChemBioDraw Ultra 14.0
(PerkinElmer Informatics, Waltham, MA, USA) and con-
verted to 3D structure by ChemBio3D Ultra 14.0 then
saved as mol format after energy minimized and Mol-
ecular Dynamic (MD) performed using MMFF94 (Merck
molecular force field) method [66]. Finally, the docking
process has been done by uploading the protein pdb
and ligand mol files to the iGEMDOCK program and
the result has been analyzed with the Discovery Studio
Visualizer Client 2020 (BIOVIA, San Diego, CA, USA).
The docking study of compounds 4e, 8e, and 9d
toward VEGFR-2 and EGFR have been achieved in com-
parison with known inhibitors including KIM, gefitinib,
sorafenib, and erlotinib (Figure 6). The fitness value
(Table 5) is the total energy of a predicted pose in the
binding site. The empirical scoring function of iGEM-
DOCK is estimated as [63]: Fitness = vdW + H-bond +
Elec; where, the vdW term is pointed out to van der
Waal energy. H-bond and Elec terms are denoted hydro-
gen bonding energy and electro statistic energy,
respectively. As illustrated in Figure 8, the docked
ligands (KIM and gefitinib) pretend the same binding
mode as the crystal one and the Root Mean Square Dis-
tance (RMSD) was within the reliable range (≤2 Å), confi-
rming the robustness of this approach.
Conclusions
A simple and an effective methodology without addition
of metal catalyst has been developed for mild construc-
tion of new coumarin analogous (4a–f, 5a,d–f, 8a–e, and
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9a,d–f) with high yield via domino amination-Knoevena-
gel condensation approach. All the synthesized com-
pounds were characterized by various spectral
methods. The anti-proliferative activity of hit com-
pounds was performed using resazurin assay. Among
them, compounds 4e and 8e that bearing 4-AMP unit
displayed the best anti-cervical cancer activity with
IC50 values of 15.5 ± 3.54 and 21 ± 4.24 µM, respectively.
Similar way was observed with 4e that showed the most
optimistic cytotoxicity result toward A549 with the IC50
value of 12.94 ± 1.51 µM. Also, 9d displayed a more sig-
nificant impact of activity against PC3 with the IC50 value
of 7.31 ± 0.48 µM. Moreover, the pooled results from the
cellular anti-proliferative potency revealed that 8d
demonstrated selectivity against PC3 (IC50 = 20.16 ±
0.07 µM), while 8e was selective toward KB-3-1 cell line
with the IC50 value of 21 ± 4.24 µM. Enzymatic inhibitory
activity disclosed that 8e is a dual inhibitor of VEGFR-2
and EGFR with IC50 values of 24.67 and 31.6 nM, which
were almost equipotent to sorafenib (31.08 nM) and
erlotinib (26.79 nM), respectively. In silico studies
showed that the estimated compounds (4e, 5e, 8d,e,
and 9d) passed all the drug-likeness metrics and they
could be valuable lead compounds for further investi-
gation in the future.
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